<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Overexpression of epidermal growth factor receptor (EGFR) is common in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, cetuximab as an EGFR-targeting drug is useful only for a subset of patients and currently no single predictor other than V-Ki-ras2 Kirsten rat <z:hpo ids='HP_0100242'>sarcoma</z:hpo> <z:mp ids='MP_0001799'>viral</z:mp> oncogene homolog (KRAS) mutation status has been established </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we investigated cetuximab accumulation in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> and major organs using (111)In-DOTA-cetuximab </plain></SENT>
<SENT sid="3" pm="."><plain>We also evaluated the potential of <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography (PET) imaging of (64)Cu-DOTA-cetuximab </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">Colorectal tumor</z:e> xenografts with a different EGFR expression level and KRAS mutation status were subjected to in vivo biodistribution study and PET imaging at 48 h post-injection of radiolabeled cetuximab </plain></SENT>
<SENT sid="5" pm="."><plain>The EGFR expression levels on <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> were determined by ex vivo immunoblotting and ELISA </plain></SENT>
<SENT sid="6" pm="."><plain>We found that KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> had significantly higher (111)In-DOTA-cetuximab accumulation than KRAS mutant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Based on KRAS mutation status, a strong correlation was found between (111)In-DOTA-cetuximab <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> uptake and EGFR expression level (KRAS <z:mp ids='MP_0002169'>wild type</z:mp>: r = 0.988; KRAS mutant: r = 0.829), and between (64)Cu-DOTA-cetuximab <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> uptake with EGFR expression level (KRAS <z:mp ids='MP_0002169'>wild type</z:mp>: r = 0.838; KRAS mutant: r = 0.927) </plain></SENT>
<SENT sid="8" pm="."><plain>Significant correlation was also found between <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> uptake of (111)In-DOTA-cetuximab and (64)Cu-DOTA-cetuximab (r = 0.920) </plain></SENT>
<SENT sid="9" pm="."><plain>PET imaging with (64)Cu-DOTA-cetuximab allowed clear visualization of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Both radiolabeled cetuximab had effectively visualized cetuximab accumulation in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumors</z:e> with a wide variety of EGFR expression levels and different KRAS mutation status as commonly encountered in the clinical setting </plain></SENT>
<SENT sid="11" pm="."><plain>Our findings suggest that this radioimmunoimaging therefore can be clinically translated as an in vivo tool to predict cetuximab accumulation in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients prior to cetuximab therapy </plain></SENT>
</text></document>